Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Vascular Biogenics (VBLT) Stock Price

News stories about Vascular Biogenics (NASDAQ:VBLT) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vascular Biogenics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.1221120449286 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Vascular Biogenics (VBLT) traded up 0.48% during mid-day trading on Wednesday, reaching $5.25. 10,479 shares of the company traded hands. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $6.70. The stock’s market capitalization is $141.80 million. The firm has a 50 day moving average of $4.67 and a 200-day moving average of $5.17.

Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. On average, equities research analysts expect that Vascular Biogenics will post ($0.74) EPS for the current fiscal year.

Several brokerages recently commented on VBLT. ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. HC Wainwright set a $11.00 price objective on shares of Vascular Biogenics and gave the company a “buy” rating in a research report on Tuesday, August 15th. Finally, Zacks Investment Research downgraded shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $12.90.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Vascular Biogenics (VBLT) Stock Price” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Insider Buying and Selling by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply